Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 2;9(4):752.
doi: 10.3390/microorganisms9040752.

An Increase in the Levels of Middle Surface Antigen Characterizes Patients Developing HBV-Driven Liver Cancer Despite Prolonged Virological Suppression

Affiliations

An Increase in the Levels of Middle Surface Antigen Characterizes Patients Developing HBV-Driven Liver Cancer Despite Prolonged Virological Suppression

Giuseppina Brancaccio et al. Microorganisms. .

Abstract

Hepatitis B virus (HBV) contains three surface glycoproteins-Large-HBs (L-HBs), Middle-HBs (M-HBs), and Small-HBs (S-HBs), known to contribute to HBV-driven pro-oncogenic properties. Here, we examined the kinetics of HBs-isoforms in virologically-suppressed patients who developed or did not develop hepatocellular carcinoma (HCC). This study enrolled 30 chronically HBV-infected cirrhotic patients under fully-suppressive anti-HBV treatment. Among them, 13 patients developed HCC. Serum samples were collected at enrolment (T0) and at HCC diagnosis or at the last control for non-HCC patients (median (range) follow-up: 38 (12-48) months). Ad-hoc ELISAs were designed to quantify L-HBs, M-HBs and S-HBs (Beacle). At T0, median (IQR) levels of S-HBs, M-HBs and L-HBs were 3140 (457-6995), 220 (31-433) and 0.2 (0-1.7) ng/mL. No significant differences in the fraction of the three HBs-isoforms were noticed between patients who developed or did not develop HCC at T0. On treatment, S-HBs showed a >25% decline or remained stable in a similar proportion of HCC and non-HCC patients (58.3% of HCC- vs. 47.1% of non-HCC patients, p = 0.6; 25% of HCC vs. 29.4% of non-HCC, p = 0.8, respectively). Conversely, M-HBs showed a >25% increase in a higher proportion of HCC compared to non-HCC patients (50% vs. 11.8%, p = 0.02), in line with M-HBs pro-oncogenic role reported in in vitro studies. No difference in L-HBs kinetics was observed in HCC and non-HCC patients. In conclusion, an increase in M-HBs levels characterizes a significant fraction of HCC-patients while under prolonged HBV suppression and stable/reduced total-HBs. The role of M-HBs kinetics in identifying patients at higher HCC risk deserves further investigation.

Keywords: HBs isoforms; HBsAg; hepatitis B; hepatocellular carcinoma; middle-HBs.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Levels at T0 of total-HBs, Small HBs S-HBs, Middle HBs (M-HBs) and Large HBs (L-HBs). The box plots report the distribution of values (ng/mL) for Total-HBs, S-HBs, M-HBs and L-HBs observed at the first analysed time-point (T0) for the overall study population (N = 30).

References

    1. Forner A., Llovet J.M., Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245–1255. doi: 10.1016/S0140-6736(11)61347-0. - DOI - PubMed
    1. El-Serag H.B. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:1264–1273. doi: 10.1053/j.gastro.2011.12.061. - DOI - PMC - PubMed
    1. Lamontagne R.J., Bagga S., Bouchard M.J. Hepatitis B virus molecular biology and pathogenesis. Hepatoma Res. 2016;2:163. doi: 10.20517/2394-5079.2016.05. - DOI - PMC - PubMed
    1. Sung J.J.Y., Tsoi K.K.F., Wong V.W.S., Li K.C.T., Chan H.L.Y. Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment. Pharmacol. Ther. 2008;28:1067–1077. doi: 10.1111/j.1365-2036.2008.03816.x. - DOI - PubMed
    1. Wu C.Y., Lin J.T., Ho H.J., Su C.W., Lee T.Y., Wang S.Y., Wu C., Wu J.C. Association of nucleos(T)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B—A nationwide cohort study. Gastroenterology. 2014;147 doi: 10.1053/j.gastro.2014.03.048. - DOI - PubMed

LinkOut - more resources